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Abstract
The Women's Health Questionnaire (WHQ) is a measure of mid-aged women's emotional and
physical health. Since its publication in 1992 the WHQ has been widely used in multinational clinical
trials, in epidemiological studies as well as in the evaluation of non-medical treatments. In particular
the WHQ has been included as a quality of life measure in trials of hormonal preparations for peri
and post menopausal women and in studies using a variety of preventative interventions for mid-
aged and older women. The questionnaire was developed in English and standardised on a sample
of women aged 45–65 years. It is reliable, has good concurrent validity and is sensitive to detecting
change, and is available in 27 languages. The range of subscales included in the WHQ enable a
detailed assessment of dimensions of emotional and physical health, such as depression, anxiety,
sleep problems, somatic symptoms, with optional subscales for menstrual problems and sexual
difficulties.
The WHQ is the first measure to be included in the MAPI Research Institute's database, the
International Health-related Quality of Life Outcomes Database (IQOD). Drawing upon data from
international studies this project aims to produce reference values for cross-culturally valid, reliable
and responsive quality of life instruments. In addition to this work, a revised shorter version of the
WHQ is currently being developed.
Why assess Health-Related Quality of Life with 
the Women's Health Questionnaire (WHQ)?
The use of health related quality of life (QOL) measures
has increased exponentially during the past 20 years.
There is clearly a need for valid and reliable instruments
that can be used in epidemiological and multinational
studies. The WHQ [1] is one of the most frequently uti-
lised measures in the assessment of QOL in mid-aged
populations of women. The WHQ was originally designed
to assess symptom perceptions during the menopause
transition and for older postmenopausal women, in
response to the lack of available instruments standardised
for this age group. It is within this age range (45–65 years)
that hormonally mediated changes, such as vasomotor
symptoms and vaginal dryness, menstrual changes and
age-related bodily changes, such as changes in sleep pat-
terns sexual behaviour and physical health, are prevalent.
These changes can confound results derived from tradi-
tional scales. By sampling a range of symptoms, the devel-
opment of the WHQ enabled examination of the
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relationships between these symptom clusters. It can be
used solely or as part of a quality of life assessment and in
the evaluation of interventions and preventative strategies
for mid-aged and older women.
What is the WHQ?
The WHQ is a 36-item questionnaire assessing nine
domains of physical and emotional health rated on four
point scales [1,2]. Partly because the WHQ was developed
to evaluate changes experienced by women during the
menopause transition it has been considered a 'disease
specific' instrument. However, the questionnaire meas-
ures a range of domains of symptom experience, some of
which are relevant to the menopause, such as vasomotor
symptoms, and others which are associated with psycho-
social factors, general health and or ageing, such as sleep
and sexual problems and cognitive difficulties. Applica-
tions of the WHQ have been varied and range from the
evaluation of hormone treatments for menopause related
problems, to epidemiological studies with populations of
healthy women. The WHQ is population specific in that it
is applied to women only. Consequently the WHQ can
also be considered to be a 'generic' QOL measure for these
mid-aged populations.
What areas of health does the WHQ measure?
The following domains are covered by the questionnaire:
• Depressed mood (6 items)
• Somatic symptoms (7 items)
• Anxiety/fears (4 items)
• Vasomotor symptoms (2 items)
• Sleep problems (3 items)
• Sexual behaviour (3 items)
• Menstrual symptoms (4 items)
• Memory/concentration (3 items)
• Attractiveness (3 items)
How was the WHQ developed?
The WHQ was developed in the 1980s by Myra Hunter at
London University [1,2]. Women aged 45 to 65 years were
recruited from a large sample of women who took part in
an ovarian screening programme in south London. Those
who had undergone surgical menopause or who were tak-
ing hormone replacement therapy (HRT) were excluded.
Eight hundred and fifty returned completed question-
naires (78% response rate). The mean age was 52.32
years, 82% were married and 66% employed outside the
home. The proportions in different socioeconomic cate-
gories were similar to the general population statistics for
women living in South East England, based on figures
taken from the UK Office of Population Censuses and Sur-
veys. The WHQ was subsequently used in a study of 106
women drawn from the age sex registers of five general
practices in South London. The means were very similar to
the norms [3,4].
Item reflecting mood states, physical sensations, vaginal
dryness, sexual interest and satisfaction, vasomotor and
menstrual symptoms were included, as well as sleep prob-
lems and other generally reported physical symptoms,
such as tiredness, headaches and dizziness. The mood
items were drawn from the Leeds' Scales for depression
and anxiety [5], because they were developed to assess
mood in general population samples, but normative data
for older women were not available at the time. Following
pilot work 36 items were selected. These were rated on
four point scales to reflect frequency – Yes, definitely; Yes,
sometimes; No, not much; No, not at all. A time frame of
the past few days was chosen to elicit current symptom
and mood states. Items were phrased both positively and
negatively.
Factor analysis (principal components with varimax rota-
tion) was used to explore the relationships between symp-
toms and to enable the development of meaningful
summary scores. Nine factors accounted for 55.7% of the
variance; these are listed as follows with the number of
items in parentheses:
Depressed mood (6), somatic symptoms (7), anxiety/
fears (4), vasomotor symptoms (2), sleep problems (3),
sexual behaviour (3), menstrual symptoms (4) and mem-
ory/concentration (3). The 'attractiveness' scale (2)
accounted for a small proportion of the variance and is
now generally omitted.
How was the WHQ validated?
Test-retest reliability was conducted on a sample of 48
women who completed the WHQ on two occasions. All
correlations were above .75, ranging from .96 to .78, sug-
gesting that the WHQ is reliable across a two-week time
interval.
Concurrent validity of the mood items was assessed by
comparison with the General Health Questionnaire
(GHQ) [6]. The 30-item version was used as this was
devised leaving out items that are frequently responded to
by people with physical illnesses [7]. The GHQ correlated
.86 with depressed mood (WHQ). Using a cut-off point of
above .43 (depressed mood scale), 87.5% of the cases
were correctly classified into those considered at risk ver-Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/41
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sus those not considered at risk of clinical depression
(GHQ>5). Using the depressed mood cut-off point,
13.6% of the standardisation sample would be classified
as cases. These figures are consistent with British commu-
nity surveys of psychological morbidity, for example
14.9% of women in Camberwell, which is the location of
the teaching hospital involved in the standardisation of
the WHQ [8].
Furthermore, a comparison of the WHQ and SF36 sub-
scales was carried out using a 50 year old sample of men-
opausal women. As expected the Depressed mood
subscale significantly correlated with the Mental Health
SF36 scale (-.70) and with the Vitality scale (-.65).
In collaboration with MAPI Research Institute a study of
the psychometric properties of the WHQ is being con-
ducted using a large data base, which include the follow-
ing language translations: Belgian Dutch, Belgian French,
Dutch, English UK, English USA, French, German, Italian,
Polish, Potuguese and Spanish. WHQ data has been
examined to provide information about the psychometric
properties of the translated versions of the scales. Provi-
sional multi-trait analysis suggests that the internal relia-
bility of the subscales is reasonable. Cronbach alpha
levels were as follows: depressed mood (.7), anxiety (.77),
somatic symptoms (.76), vasomotor symptoms (.84),
sleep problems (.73); for menstrual problems and sexual
problems the coefficients were lower, being .64 and .59
respectively. Further analyses will include an examination
of the relationships between items of the WHQ for the dif-
ferent samples, in order to develop a revised version of the
WHQ. This is a development which forms part of the
IQOD project (see section below)
In which populations has the WHQ been used?
The WHQ has been applied in studies of healthy mid-
aged women [9], in peri and post menopausal women
seeking help and being treated for menopausal problems,
for example with vasomotor symptoms, sexual problems
or emotional problems or who might be seeking prevent-
ative treatment for osteoporosis [10–13], and in samples
of women who experience menopausal symptoms follow-
ing treatment for breast cancer.
What translations are available?
The WHQ has been translated into the following lan-
guages (by MAPI Research Institute (27, rue de la Villette,
69003 Lyon, France who can be contacted to obtain trans-
lated questionnaires)): Afrikaans, Bulgarian, Croatian,
Czech, Danish, Dutch, Dutch for Belgium, English for
Australia, English for Canada, English for the USA, Finn-
ish [14], French, French for Belgium, German, Hungarian,
Italian [15,16], Norwegian, Polish, Portuguese, Portu-
guese for Brazil, Romanian, Spanish, Spanish for Argen-
tina, Spanish for Chile, Spanish for Mexico, Spanish for
USA, Swedish [17].
What are the applications of the WHQ?
The WHQ is widely used to assess health related QOL in
samples of healthy women and in those seeking help for
specific physical or emotional problems. It has been used
in a series of cross-sectional and prospective studies of
mid-aged women by the author and co-workers [4,9,18].
However, the main application has been the evaluation of
the efficacy of medical and non-medical interventions for
specific symptoms and upon health related quality of life.
The WHQ has been and is currently being used in a
number of national and multinational clinical trials of
hormonal preparations for menopausal and postmeno-
pausal women [11–13,19–28]. For example, in the U.K.
the WHQ has been included in the WISDOM trial as part
of a detailed evaluation of quality of life changes follow-
ing hormonal treatment [19]. The scale is also being used
to evaluate the effects of hormone replacement therapy in
a large randomised controlled trial of breast cancer
patients in the U.K., as well as in a study of the impact of
Tamoxifen.
Similarly, the WHQ has been used to evaluate quality of
life outcomes following non-medical interventions. For
example, a health education intervention in primary care
was implemented with the aims of providing information
with relevance to the menopause to 45 year old women.
The WHQ was used to assess change post intervention and
five years later when the sample were aged 50 years [4,9].
In an Australian study, Slaven and Lee [29,30] found that
women who exercised obtained lower depressed mood
and anxiety (WHQ) scores than non-exercisers, regardless
of menopausal status. Exercising women also obtained
lower scores on the somatic symptoms and memory and
concentration subscales. In a prospective phase of this
study the acute effects of aerobic exercise were examined;
significant enhancements in mood and reductions in
reported somatic and vasomotor symptom subscales were
evident immediately following an aerobic exercise class.
A cognitive-behavioural treatment (CBT) for menopausal
hot flushes has been developed and was evaluated using
the WHQ [31]. Other options offered to the women were
no treatment or HRT, in a patient preference design. Both
active treatments significantly reduced hot flush fre-
quency, but for the CBT group depressed mood (WHQ)
and anxiety (WHQ) also significantly reduced – thus the
WHQ discriminated between treatment effects. Prelimi-
nary work suggests that this treatment might also be use-
ful for women who experience troublesome menopausal
symptoms following treatment for breast cancer and for
whom hormonal treatments are contraindicated.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/41
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The need for the evaluation of complementary therapies is
now being recognised and the WHQ has been applied in
studies of the efficacy of ginseng [32], reflexology [33] and
acupuncture (in progress) for menopausal symptoms.
How is the WHQ administered and how long 
does it take?
The WHQ is usually self-administered and has been
found to be easy to complete. It can be used in postal sur-
veys and has also been used in telephone assessments. The
time period for completion is typically 5 minutes.
How is the WHQ scored?
Scoring of the WHQ is straight forward. The four point
scales (yes definitely, yes sometimes, not not much, no
not at all) are reduced to binary options (0/1) and the
subscale items are summated and divided by the number
of items in each subscale. Norms are available for the 45–
65 age range (n = 682), the 45–54 age range (n = 474) and
the 55–65 age range (n = 179), as well as for a younger
sample, aged 23–38 (n = 55) [1]. The menstrual and sex-
ual domains should be scored separately as they may not
be applicable to all participants, for example postmeno-
pausal women or those who are not currently sexually
active. Scoring instructions are in preparation: please con-
tact Mapi Research Institute for further information.
Is the WHQ responsive to change, and what is a 
meaningful change for WHQ subscale scores?
The WHQ has been used to evaluate HRT trials, psycho-
logical interventions and preventative initiatives for mid-
aged and older women. For example, Wiklund and col-
leagues [11] demonstrated that the WHQ was sensitive to
detecting change in response to HRT across all subscales,
in a one year prospective study of 110 women, and in a
randomised placebo controlled trial [12]. Similarly, in a
randomised comparison of transdermal oestrogen and a
symptomatic treatment (veralipride) all subscales, except
the menstruation subscale, significantly discriminated
between treatments [13]. For a comparison of measures
including the WHQ, see Wiklund [34]. A meaningful clin-
ically significant change on subscales of the WHQ would
typically be a difference of approximately 0.10 to 0.20. As
well as detecting benefits of treatments, some items of the
WHQ, such as breast tenderness and nausea, are those
reported as side effects of some treatment regimes.
Is there an item Banking on the WHQ?
The WHQ is the first QOL measure to be included in the
International Health-related Quality of Life Outcomes
Database (IQOD) (see http://www.iqod.org), which has
been initiated by MAPI Research Institute [see: http://
www.qolid.org/]. This project aims to develop reference
values, item banking and psychometric validation of lin-
guistically validated QOL instruments, using pooled data
form international studies. The database contains base-
line QOL, sociodemographic and clinical data from inter-
national clinical or epidemiological studies. This is an
exciting development, which will aid the interpretation
and comparisons of data across populations and across
disease and symptom states.
What is the availability and cost of using the 
WHQ?
Copyright: Dr Myra Hunter
Conditions of use: free access with author's written per-
mission for academic/non profit research with fees for
commercial/pharmaceutical companies. The distribution
of the WHQ and user agreements are administered by
MAPI (website: http://www.mapi-research-inst.org).
Groups who have independently translated the WHQ
may charge for their versions.
Who may I contact to obtain a copy of the WHQ 
or more information about the WHQ?
For information on, or permission to use the question-
naire in all languages, please contact:
Mapi Research Institute
27, rue de la Villette
69003 Lyon France
Phone: +33 (0)4 72 13 66 67
Fax: +33 (0)4 72 13 66 82
E-mail: instdoc@mapi.fr
Website: http://www.mapi-research-inst.org
For any request, please consult Mapi Research Institute
website, "Distribution of Health Outcomes Instruments"
section.
Conclusions
The Women's Health Questionnaire is a reliable and valid
measure of women's perceptions of emotional and physi-
cal health. It is being widely used in evaluations of medi-
cal and non-medical treatment regimes and preventative
interventions for peri- and postmenopausal women in
Europe, Australia and North and South America, and is
sensitive in detecting treatment effects and side effects.
Current and future developments include the WHQ data-
base, which is part of the IQOD project, and the publica-
tion of a revised version of the WHQ.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/41
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